BMND07, or BMND-07, is a combination of either dimethyltryptamine (DMT) or 5-MeO-DMT and another undisclosed compound which is under development for the treatment of depressive disorders. It is being developed by Biomind Labs. As of March 2022, it is in phase 1 clinical trials.
See also List of investigational hallucinogens and entactogens List of investigational antidepressants
References
External links Pipeline - Biomind Labs